Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Varpuluoma, Outi
37  Ergebnisse:
Personensuche X
?
1

Epidemiology and Comorbidities of Mucous Membrane Pemphigoi..:

Leisti, Päivi ; Huilaja, Laura ; Jokelainen, Jari..
Journal of Investigative Dermatology.  , 2024
Link: https://doi.org/10.1016/..
 
?
2

Solid and hematological malignancies in patients with bullo..:

Varpuluoma, Outi ; Jokelainen, Jari ; Huilaja, Laura.
Journal of the American Academy of Dermatology.  90 (2024)  2 - p. 399-401 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphig..:

Tuusa, Jussi ; Kokkonen, Nina ; Mattila, Anja...
Journal of Investigative Dermatology.  143 (2023)  1 - p. 78-86.e12 , 2023
Link: https://doi.org/10.1016/..
 
?
4

Reply to: Comment on "Bullous pemphigoid and neuropsychiatr..:

Varpuluoma, Outi ; Jokelainen, Jari ; Tasanen, Kaisa.
Journal of the American Academy of Dermatology.  88 (2023)  3 - p. e139 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Accurate diagnosis of bullous pemphigoid requires multiple ..:

Leisti, Päivi ; Pankakoski, Anna ; Jokelainen, Jari...
Frontiers in Immunology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
6

Ulcerative Tuberculosis in a Patient Treated with Adalimuma:

Varpuluoma, Outi ; Sinikumpu, Suvi-Päivikki ; Jackson, Päivi..
Acta Dermato-Venereologica.  102 (2022)  - p. adv00700 , 2022
Link: https://doi.org/10.2340/..
 
?
7

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous p..:

Nätynki, Antti ; Leisti, Päivi ; Tuusa, Jussi...
Frontiers in Immunology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
8

GLP-1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of ..:

Varpuluoma, Outi ; Jokelainen, Jari ; Huilaja, Laura.
Journal of Investigative Dermatology.  141 (2021)  12 - p. 2969-2972.e1 , 2021
Link: https://doi.org/10.1016/..
 
?
9

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphig..:

Tasanen, Kaisa ; Varpuluoma, Outi ; Nishie, Wataru
Frontiers in Immunology.  10 (2019)  - p. , 2019
Link: https://doi.org/10.3389/..
 
?
10

Reply to: "Comment on 'Oral diabetes medications other than..:

Varpuluoma, Outi ; Tasanen, Kaisa ; Huilaja, Laura
Journal of the American Academy of Dermatology.  80 (2019)  6 - p. e191-e192 , 2019
Link: https://doi.org/10.1016/..
 
?
11

Drugs used for neurologic and psychiatric conditions increa..:

Varpuluoma, Outi ; Jokelainen, Jari ; Försti, Anna-Kaisa...
Journal of the American Academy of Dermatology.  81 (2019)  1 - p. 250-253 , 2019
Link: https://doi.org/10.1016/..
 
?
12

Oral diabetes medications other than dipeptidyl peptidase 4..:

Varpuluoma, Outi ; Försti, Anna-Kaisa ; Jokelainen, Jari...
Journal of the American Academy of Dermatology.  79 (2018)  6 - p. 1034-1038.e5 , 2018
Link: https://doi.org/10.1016/..
 
?
13

Reply to: "Comment on 'Oral diabetes medications other than..:

Varpuluoma, Outi ; Huilaja, Laura ; Tasanen, Kaisa
Journal of the American Academy of Dermatology.  79 (2018)  6 - p. e113-e114 , 2018
Link: https://doi.org/10.1016/..
 
?
14

Accurate diagnosis of bullous pemphigoid requires multiple ..:

Leisti, Päivi ; Pankakoski, Anna ; Jokelainen, Jari...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10711056/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
15

Accurate diagnosis of bullous pemphigoid requires multiple ..:

Leisti, Päivi ; Pankakoski, Anna ; Jokelainen, Jari...
10.3389/fimmu.2023.1281302.  , 2023
Link: http://hdl.handle.net/10..
 
1-15